Metastatic Breast Cancer - Pipeline Review, Q3 2011

Metastatic Breast Cancer - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Metastatic Breast Cancer - Pipeline Review, Q3 2011', provides an overview of the Metastatic Breast Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer. 'Metastatic Breast Cancer - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Breast Cancer.
- A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Breast Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Metastatic Breast Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Metastatic Breast Cancer Overview
Therapeutics Development
Metastatic Breast Cancer Therapeutics under Development by Companies
Metastatic Breast Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Metastatic Breast Cancer Therapeutics - Products under Development by Companies
Metastatic Breast Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Breast Cancer Therapeutics Development
Metastatic Breast Cancer - Therapeutics Assessment
Late Stage Drug Profiles
Metastatic Breast Cancer Therapeutics – Drug Profile Updates
Metastatic Breast Cancer Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Metastatic Breast Cancer, Q3 2011
Products under Development for Metastatic Breast Cancer – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Bristol-Myers Squibb Company, 2011
Boehringer Ingelheim GmbH, 2011
F. Hoffmann-La Roche Ltd., 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Abbott Laboratories, 2011
Biogen Idec Inc., 2011
Amgen Inc., 2011
Sanofi-Aventis, 2011
Adherex Technologies Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Bavarian Nordic A/S, 2011
Daiichi Sankyo Company, Ltd, 2011
Merck & Co., Inc., 2011
Dainippon Sumitomo Pharma Co., Ltd., 2011
Infinity Pharmaceuticals, Inc., 2011
Takeda Pharmaceutical Company Limited, 2011
Celltrion, Inc., 2011
Novartis AG, 2011
ImClone Systems Incorporated, 2011
Astellas Pharma Inc., 2011
Chugai Pharmaceutical Co. Ltd, 2011
Pfizer Inc., 2011
Santaris Pharma A/S, 2011
Celgene Corporation, 2011
Bayer AG, 2011
Incyte Corporation, 2011
Geron Corporation, 2011
Merck KGaA, 2011
EntreMed, Inc., 2011
InNexus Biotechnology Inc., 2011
Peregrine Pharmaceuticals, Inc., 2011
Allos Therapeutics, Inc, 2011
iOMEDICO AG, 2011
Array BioPharma Inc., 2011
Natco Pharma Limited, 2011
Piramal Life Sciences Limited, 2011
Universita degli Studi di Modena e Reggio Emilia, 2011
BioNumerik Pharmaceuticals, Inc., 2011
Cytheris SA, 2011
Quantum Immunologics, Inc., 2011
PTC Therapeutics, Inc., 2011
Marillion Pharmaceuticals, Inc., 2011
Immutep S.A., 2011
Syndax Pharmaceuticals, Inc., 2011
NewLink Genetics Corporation, 2011
Sopherion Therapeutics, LLC, 2011
AVEO Pharmaceuticals, Inc., 2011
TRACON Pharmaceuticals, Inc., 2011
Regulon Inc., 2011
Pharmatech Oncology, Inc, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Metastatic Breast Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Metastatic Breast Cancer, Q3 2011
Products under Development for Metastatic Breast Cancer – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011